APA (7th ed.) Citation

Ricci, F., Guffanti, F., Damia, G., & Broggini, M. (2017). Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts. Molecular Cancer, 16, 1. https://doi.org/10.1186/s12943-017-0662-3

Chicago Style (17th ed.) Citation

Ricci, Francesca, Federica Guffanti, Giovanna Damia, and Massimo Broggini. "Combination of Paclitaxel, Bevacizumab and MEK162 in Second Line Treatment in Platinum-relapsing Patient Derived Ovarian Cancer Xenografts." Molecular Cancer 16 (2017): 1. https://doi.org/10.1186/s12943-017-0662-3.

MLA (9th ed.) Citation

Ricci, Francesca, et al. "Combination of Paclitaxel, Bevacizumab and MEK162 in Second Line Treatment in Platinum-relapsing Patient Derived Ovarian Cancer Xenografts." Molecular Cancer, vol. 16, 2017, p. 1, https://doi.org/10.1186/s12943-017-0662-3.